Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation
Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing. To determine steady-state apixaban peak and trough concentrations during routine care of ol...
Gespeichert in:
| Veröffentlicht in: | JACC. Advances (Online) 2022-06, Vol.1 (2), p.100039, Article 100039 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 100039 |
| container_title | JACC. Advances (Online) |
| container_volume | 1 |
| creator | Thomas, Alveena Fang, Margaret C Kogan, Scott Hubbard, Colin C Friedman, Paula N Gong, Li Klein, Teri E Nutescu, Edith A O'Brien, Travis J Tuck, Matthew Perera, Minoli A Schwartz, Janice B |
| description | Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing.
To determine steady-state apixaban peak and trough concentrations during routine care of older adults with NVAF, compare concentrations to clinical trial concentrations, and explore factors associated with concentrations.
A cross-sectional study of medically stable older adults with NVAF (≥75 years or ≥70 years if Black) receiving apixaban. Peak (2-4.4 hours post-dose) and trough (before next dose) concentrations were determined by anti-Xa activity calibrated chromogenic assay. Patient characteristics associated with concentrations were determined by multivariate modeling.
The median age of patients (n = 115) was 80 (interquartile range: 77-84) years. The cohort comprised 46 women and 69 men; of which 98 are White, 11 Black, and 6 Asian. With 5 mg twice daily per labelling (n = 88), peak concentrations were higher in women: 248 ± 105 vs 174 ± 67 ng/mL in men (
< 0.001) and exceeded expected 95% range in 6 of 30 vs 0 of 55 men (
= 0.002). With 2.5 mg twice daily per label (n = 11), concentrations were |
| doi_str_mv | 10.1016/j.jacadv.2022.100039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10643025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2889995963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3799-cdbc74bf499255d6e9380e4bf9deacf3073dc4c8726d2e7e4f466c84094d85053</originalsourceid><addsrcrecordid>eNpVkVFLBCEUhSWKiuofRPjYy26OOs74FMvQVhAFUdSbOOqUi6ubziz173ObinpSjuce770fAMcFmhaoYGeL6UIqqddTjDDOEkKEb4F9XFV4whl53v5z3wNHKS2yBXNOGCW7YI9UnBWoYvvAzFb2XbbSwyZ4ZXwfZW-DT9B6eB-G3noDG2e9VdLBRkYDQwfvnDYRzvTg-gSfbP8Kb4NfS7cenMx6H202z20brXNfcYdgp5MumaPv8wA8zi8emqvJzd3ldTO7majcEZ8o3aqKth3lHJelZoaTGpkscG2k6giqiFZU1RVmGpvK0I4ypmqKONV1iUpyAM7H3NXQLo0e53FiFe1Sxg8RpBX_X7x9FS9hLQqUF4PwJuH0OyGGt8GkXixtUibP4U0YksB1zTkv816zlY5WFUNK0XS__xRIbCiJhRgpiQ0lMVLKZSd_e_wt-mFCPgEhPpHm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2889995963</pqid></control><display><type>article</type><title>Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Thomas, Alveena ; Fang, Margaret C ; Kogan, Scott ; Hubbard, Colin C ; Friedman, Paula N ; Gong, Li ; Klein, Teri E ; Nutescu, Edith A ; O'Brien, Travis J ; Tuck, Matthew ; Perera, Minoli A ; Schwartz, Janice B</creator><creatorcontrib>Thomas, Alveena ; Fang, Margaret C ; Kogan, Scott ; Hubbard, Colin C ; Friedman, Paula N ; Gong, Li ; Klein, Teri E ; Nutescu, Edith A ; O'Brien, Travis J ; Tuck, Matthew ; Perera, Minoli A ; Schwartz, Janice B</creatorcontrib><description>Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing.
To determine steady-state apixaban peak and trough concentrations during routine care of older adults with NVAF, compare concentrations to clinical trial concentrations, and explore factors associated with concentrations.
A cross-sectional study of medically stable older adults with NVAF (≥75 years or ≥70 years if Black) receiving apixaban. Peak (2-4.4 hours post-dose) and trough (before next dose) concentrations were determined by anti-Xa activity calibrated chromogenic assay. Patient characteristics associated with concentrations were determined by multivariate modeling.
The median age of patients (n = 115) was 80 (interquartile range: 77-84) years. The cohort comprised 46 women and 69 men; of which 98 are White, 11 Black, and 6 Asian. With 5 mg twice daily per labelling (n = 88), peak concentrations were higher in women: 248 ± 105 vs 174 ± 67 ng/mL in men (
< 0.001) and exceeded expected 95% range in 6 of 30 vs 0 of 55 men (
= 0.002). With 2.5 mg twice daily per label (n = 11), concentrations were <5 mg twice daily (peak: 136 ± 87 vs 201 ± 90 ng/mL,
= 0.026; trough: 65 ± 28 vs 109 ± 56 ng/mL,
< 0.001), but not different than 2.5 mg twice daily without reduction criteria (n = 13; peak: 132 ± 88; trough: 65 ± 31 ng/mL). Covariates associated with concentrations included sex, number of daily medications, and creatinine clearance.
Older women had higher than expected peak apixaban concentrations, and 2.5 mg twice daily produced lower concentrations than standard dosing. Factors not currently included in dosing recommendations affected concentrations. The impact of apixaban concentrations on outcomes needs evaluation.</description><identifier>ISSN: 2772-963X</identifier><identifier>EISSN: 2772-963X</identifier><identifier>DOI: 10.1016/j.jacadv.2022.100039</identifier><identifier>PMID: 37961076</identifier><language>eng</language><publisher>United States</publisher><ispartof>JACC. Advances (Online), 2022-06, Vol.1 (2), p.100039, Article 100039</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3799-cdbc74bf499255d6e9380e4bf9deacf3073dc4c8726d2e7e4f466c84094d85053</citedby><cites>FETCH-LOGICAL-c3799-cdbc74bf499255d6e9380e4bf9deacf3073dc4c8726d2e7e4f466c84094d85053</cites><orcidid>0000-0003-3362-1543</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643025/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643025/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37961076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Alveena</creatorcontrib><creatorcontrib>Fang, Margaret C</creatorcontrib><creatorcontrib>Kogan, Scott</creatorcontrib><creatorcontrib>Hubbard, Colin C</creatorcontrib><creatorcontrib>Friedman, Paula N</creatorcontrib><creatorcontrib>Gong, Li</creatorcontrib><creatorcontrib>Klein, Teri E</creatorcontrib><creatorcontrib>Nutescu, Edith A</creatorcontrib><creatorcontrib>O'Brien, Travis J</creatorcontrib><creatorcontrib>Tuck, Matthew</creatorcontrib><creatorcontrib>Perera, Minoli A</creatorcontrib><creatorcontrib>Schwartz, Janice B</creatorcontrib><title>Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation</title><title>JACC. Advances (Online)</title><addtitle>JACC Adv</addtitle><description>Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing.
To determine steady-state apixaban peak and trough concentrations during routine care of older adults with NVAF, compare concentrations to clinical trial concentrations, and explore factors associated with concentrations.
A cross-sectional study of medically stable older adults with NVAF (≥75 years or ≥70 years if Black) receiving apixaban. Peak (2-4.4 hours post-dose) and trough (before next dose) concentrations were determined by anti-Xa activity calibrated chromogenic assay. Patient characteristics associated with concentrations were determined by multivariate modeling.
The median age of patients (n = 115) was 80 (interquartile range: 77-84) years. The cohort comprised 46 women and 69 men; of which 98 are White, 11 Black, and 6 Asian. With 5 mg twice daily per labelling (n = 88), peak concentrations were higher in women: 248 ± 105 vs 174 ± 67 ng/mL in men (
< 0.001) and exceeded expected 95% range in 6 of 30 vs 0 of 55 men (
= 0.002). With 2.5 mg twice daily per label (n = 11), concentrations were <5 mg twice daily (peak: 136 ± 87 vs 201 ± 90 ng/mL,
= 0.026; trough: 65 ± 28 vs 109 ± 56 ng/mL,
< 0.001), but not different than 2.5 mg twice daily without reduction criteria (n = 13; peak: 132 ± 88; trough: 65 ± 31 ng/mL). Covariates associated with concentrations included sex, number of daily medications, and creatinine clearance.
Older women had higher than expected peak apixaban concentrations, and 2.5 mg twice daily produced lower concentrations than standard dosing. Factors not currently included in dosing recommendations affected concentrations. The impact of apixaban concentrations on outcomes needs evaluation.</description><issn>2772-963X</issn><issn>2772-963X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkVFLBCEUhSWKiuofRPjYy26OOs74FMvQVhAFUdSbOOqUi6ubziz173ObinpSjuce770fAMcFmhaoYGeL6UIqqddTjDDOEkKEb4F9XFV4whl53v5z3wNHKS2yBXNOGCW7YI9UnBWoYvvAzFb2XbbSwyZ4ZXwfZW-DT9B6eB-G3noDG2e9VdLBRkYDQwfvnDYRzvTg-gSfbP8Kb4NfS7cenMx6H202z20brXNfcYdgp5MumaPv8wA8zi8emqvJzd3ldTO7majcEZ8o3aqKth3lHJelZoaTGpkscG2k6giqiFZU1RVmGpvK0I4ypmqKONV1iUpyAM7H3NXQLo0e53FiFe1Sxg8RpBX_X7x9FS9hLQqUF4PwJuH0OyGGt8GkXixtUibP4U0YksB1zTkv816zlY5WFUNK0XS__xRIbCiJhRgpiQ0lMVLKZSd_e_wt-mFCPgEhPpHm</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Thomas, Alveena</creator><creator>Fang, Margaret C</creator><creator>Kogan, Scott</creator><creator>Hubbard, Colin C</creator><creator>Friedman, Paula N</creator><creator>Gong, Li</creator><creator>Klein, Teri E</creator><creator>Nutescu, Edith A</creator><creator>O'Brien, Travis J</creator><creator>Tuck, Matthew</creator><creator>Perera, Minoli A</creator><creator>Schwartz, Janice B</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3362-1543</orcidid></search><sort><creationdate>20220601</creationdate><title>Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation</title><author>Thomas, Alveena ; Fang, Margaret C ; Kogan, Scott ; Hubbard, Colin C ; Friedman, Paula N ; Gong, Li ; Klein, Teri E ; Nutescu, Edith A ; O'Brien, Travis J ; Tuck, Matthew ; Perera, Minoli A ; Schwartz, Janice B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3799-cdbc74bf499255d6e9380e4bf9deacf3073dc4c8726d2e7e4f466c84094d85053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Alveena</creatorcontrib><creatorcontrib>Fang, Margaret C</creatorcontrib><creatorcontrib>Kogan, Scott</creatorcontrib><creatorcontrib>Hubbard, Colin C</creatorcontrib><creatorcontrib>Friedman, Paula N</creatorcontrib><creatorcontrib>Gong, Li</creatorcontrib><creatorcontrib>Klein, Teri E</creatorcontrib><creatorcontrib>Nutescu, Edith A</creatorcontrib><creatorcontrib>O'Brien, Travis J</creatorcontrib><creatorcontrib>Tuck, Matthew</creatorcontrib><creatorcontrib>Perera, Minoli A</creatorcontrib><creatorcontrib>Schwartz, Janice B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JACC. Advances (Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Alveena</au><au>Fang, Margaret C</au><au>Kogan, Scott</au><au>Hubbard, Colin C</au><au>Friedman, Paula N</au><au>Gong, Li</au><au>Klein, Teri E</au><au>Nutescu, Edith A</au><au>O'Brien, Travis J</au><au>Tuck, Matthew</au><au>Perera, Minoli A</au><au>Schwartz, Janice B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation</atitle><jtitle>JACC. Advances (Online)</jtitle><addtitle>JACC Adv</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>1</volume><issue>2</issue><spage>100039</spage><pages>100039-</pages><artnum>100039</artnum><issn>2772-963X</issn><eissn>2772-963X</eissn><abstract>Direct-acting oral anticoagulants are first-line agents for prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF), but data are limited for the oldest patients, and with reduced dosing.
To determine steady-state apixaban peak and trough concentrations during routine care of older adults with NVAF, compare concentrations to clinical trial concentrations, and explore factors associated with concentrations.
A cross-sectional study of medically stable older adults with NVAF (≥75 years or ≥70 years if Black) receiving apixaban. Peak (2-4.4 hours post-dose) and trough (before next dose) concentrations were determined by anti-Xa activity calibrated chromogenic assay. Patient characteristics associated with concentrations were determined by multivariate modeling.
The median age of patients (n = 115) was 80 (interquartile range: 77-84) years. The cohort comprised 46 women and 69 men; of which 98 are White, 11 Black, and 6 Asian. With 5 mg twice daily per labelling (n = 88), peak concentrations were higher in women: 248 ± 105 vs 174 ± 67 ng/mL in men (
< 0.001) and exceeded expected 95% range in 6 of 30 vs 0 of 55 men (
= 0.002). With 2.5 mg twice daily per label (n = 11), concentrations were <5 mg twice daily (peak: 136 ± 87 vs 201 ± 90 ng/mL,
= 0.026; trough: 65 ± 28 vs 109 ± 56 ng/mL,
< 0.001), but not different than 2.5 mg twice daily without reduction criteria (n = 13; peak: 132 ± 88; trough: 65 ± 31 ng/mL). Covariates associated with concentrations included sex, number of daily medications, and creatinine clearance.
Older women had higher than expected peak apixaban concentrations, and 2.5 mg twice daily produced lower concentrations than standard dosing. Factors not currently included in dosing recommendations affected concentrations. The impact of apixaban concentrations on outcomes needs evaluation.</abstract><cop>United States</cop><pmid>37961076</pmid><doi>10.1016/j.jacadv.2022.100039</doi><orcidid>https://orcid.org/0000-0003-3362-1543</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2772-963X |
| ispartof | JACC. Advances (Online), 2022-06, Vol.1 (2), p.100039, Article 100039 |
| issn | 2772-963X 2772-963X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10643025 |
| source | DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| title | Apixaban Concentrations in Routine Clinical Care of Older Adults With Nonvalvular Atrial Fibrillation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A18%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apixaban%20Concentrations%20in%20Routine%20Clinical%20Care%20of%20Older%20Adults%20With%20Nonvalvular%20Atrial%20Fibrillation&rft.jtitle=JACC.%20Advances%20(Online)&rft.au=Thomas,%20Alveena&rft.date=2022-06-01&rft.volume=1&rft.issue=2&rft.spage=100039&rft.pages=100039-&rft.artnum=100039&rft.issn=2772-963X&rft.eissn=2772-963X&rft_id=info:doi/10.1016/j.jacadv.2022.100039&rft_dat=%3Cproquest_pubme%3E2889995963%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2889995963&rft_id=info:pmid/37961076&rfr_iscdi=true |